Evox Therapeutics Ltd collaborates with Rett Syndrome Research Trust to evaluate its ExoEdit® exosome-based gene editing platform as a potential therapeutic approach for Rett syndrome.
Evox Therapeutics Ltd has announced the launch of a new strategic collaboration with the Rett Syndrome Research Trust (RSRT) to explore the potential of its proprietary ExoEdit® gene editing platform as a treatment approach for Rett syndrome. The partnership represents an important step toward addressing one of the most challenging obstacles in neurological gene therapy: safely and effectively delivering gene editing tools to the brain.
Advancing Gene Editing for Neurological Disease
Evox is a biotechnology company focused on developing transformative therapies for genetically driven neurodegenerative and rare diseases. Its core innovation lies in harnessing engineered exosomes—naturally occurring extracellular vesicles—to deliver therapeutic payloads directly to target tissues. Through its ExoEdit® platform, Evox aims to enable precise gene editing by packaging editing machinery inside exosomes capable of crossing biological barriers, including the blood–brain barrier.
Gene editing technologies have rapidly advanced in recent years, offering the potential to correct disease-causing mutations at their source. However, one of the primary limitations of gene editing in neurological disorders has been delivery. Traditional viral vectors, while effective in some contexts, raise safety concerns, immunogenicity risks, and manufacturing complexities. Moreover, achieving broad and efficient distribution of editing cargo across the central nervous system (CNS) remains difficult.
The collaboration between Evox and RSRT seeks to evaluate whether ExoEdit® can overcome these barriers by enabling non-viral, exosome-based delivery of gene editing components to the brain. If successful, the effort could lay the groundwork for a new generation of CNS-targeted genetic medicines.
Understanding Rett Syndrome
Rett syndrome is a rare but severe neurodevelopmental disorder that predominantly affects girls. Symptoms typically emerge after an initial period of seemingly normal development, often between 6 and 18 months of age. Children with Rett syndrome experience a progressive loss of motor skills, spoken language, and purposeful hand movements. Many develop repetitive hand behaviors, seizures, breathing irregularities, scoliosis, and gastrointestinal complications. The disorder profoundly impacts quality of life and generally requires lifelong, around-the-clock care supported by multidisciplinary medical teams.
The majority of Rett syndrome cases are caused by mutations in the MECP2 gene, which plays a crucial role in regulating gene expression in neurons. Disruption of MECP2 function leads to widespread neurological dysfunction. Importantly, because Rett syndrome arises from a single gene mutation in most patients, it is considered a strong candidate for gene-targeted therapeutic approaches.
Preclinical studies in animal models have demonstrated that restoring MECP2 function—even after symptoms appear—can lead to significant improvement. These findings have fueled optimism that gene editing or gene replacement strategies could potentially reverse aspects of the disease, rather than merely manage symptoms. However, safe and efficient delivery of therapeutic agents to neurons throughout the brain has remained a formidable challenge.
The Promise of ExoEdit® Technology
Evox’s ExoEdit® platform is designed to address precisely this challenge. Exosomes are naturally occurring vesicles released by cells to transport proteins, RNA, and other molecules between cells. Because they are biologically derived, exosomes are generally well tolerated by the body and may carry a lower risk of immune activation compared to viral vectors.
Through advanced engineering techniques, Evox modifies exosomes to carry gene editing tools—such as CRISPR-based systems—directly to specific tissues, including the CNS. By leveraging the intrinsic biological properties of exosomes, the company aims to achieve broad brain distribution while minimizing toxicity and off-target effects.
According to Evox leadership, ExoEdit® holds the potential to deliver gene editing cargo safely and effectively to the brain, enabling correction of the underlying genetic mutations responsible for diseases like Rett syndrome. If the platform proves capable of widespread CNS delivery, it could represent a major technological breakthrough not only for Rett syndrome but also for other neurogenetic conditions.
A Mission-Driven Partnership
The collaboration with RSRT underscores the shared commitment of both organizations to accelerating therapeutic development for Rett syndrome. RSRT is a nonprofit organization dedicated to advancing research toward a cure for Rett syndrome through strategic funding, scientific partnerships, and translational initiatives. Over the years, RSRT has played a pivotal role in supporting research programs focused on gene therapy, gene editing, and other innovative approaches.
Monica Coenraads, Founder and CEO of RSRT and a parent of an adult daughter with Rett syndrome, emphasized the importance of overcoming delivery barriers in gene editing. Non-viral delivery to the brain has long been considered a critical hurdle in the field. RSRT sees significant promise in Evox’s exosome-based approach as a potential solution that could safely distribute editing tools throughout the brain.
The collaboration will initially focus on assessing feasibility—examining whether ExoEdit® can effectively transport gene editing components targeting MECP2 mutations across relevant preclinical models. Data generated through this research may inform decisions regarding a potential expanded preclinical development program.
Potential Impact on the Rett Community
If the collaboration demonstrates successful CNS delivery and functional gene correction, it could mark a pivotal turning point for the Rett community. Current treatment options primarily address symptoms such as seizures, breathing abnormalities, and motor difficulties, but they do not target the root genetic cause of the disorder.
A gene editing therapy capable of correcting MECP2 mutations could potentially provide long-lasting or even permanent therapeutic benefit. Because Rett syndrome affects multiple systems and functions, a disease-modifying therapy could significantly improve independence, communication ability, and overall quality of life for patients and families.
Furthermore, advances made through this program could extend beyond Rett syndrome. Many neurodevelopmental and neurodegenerative disorders are caused by single-gene mutations. A validated, scalable, non-viral delivery platform for CNS gene editing could unlock therapeutic opportunities for a wide range of rare and common neurological diseases.
